abstract Biologics have been a key component of severe asthma treatment, and there are
currently biologics available that target IgE, IL-5, IL-4/IL-13, and TSLP. Randomized …

Introduction In recent years, monoclonal antibodies targeting Type-2 inflammatory pathways
have been developed for severe asthma treatment. However, even when patients are …

Background Many patients with severe asthma require chronic corticosteroid treatment to
maintain asthma control. Research Question Are the reduction in oral corticosteroid (OCS) …

Background Patients with severe asthma may present with characteristics representing
overlapping phenotypes, making them eligible for more than one class of biologic. Our aim …

Atopic dermatitis (AD) is an itchy, non-contagious relapsing and chronic inflammatory skin
disease that usually develops in early childhood. This pathology is associated with food …

Purpose Treatment of severe asthma has made great strides thanks to rapid progress in
understanding immune response and inflammatory pathways. This led to the advent of the …

Omalizumab is the first monoclonal antibody that was globally approved as a personalized
treatment option for patients with moderate-to-severe allergic asthma. This review …

Asthma is a heterogeneous chronic inflammatory airway disease that imposes a great
burden on public health worldwide. In the past two years, fundamental changes have been …

Introduction: Asthma is a chronic disease, characterized by reversible airway obstruction,
hypersensitivity reactions, and inflammation. Oral corticosteroids are an important treatment …

The basis of our current understanding of allergies begins with the discovery of IgE in the
mid-1960s. The whole theory of the physiology and pathophysiology of allergic diseases …